Compound Detail
CHEMBL1690
HYDROXYCHLOROQUINE SULFATE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL1690 |
| Name | HYDROXYCHLOROQUINE SULFATE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | JCBIVZZPXRZKTI-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
| Parent Compound | CHEMBL1535 |
| Active Moiety | CHEMBL1535 |
1
Targets
4
Activities
2
Assay Types
0
PK Parameters
20
Publications
11
Known Names
15
Indications
3
Mechanisms
Molecular Properties
335.9
MW (Da)
3.78
ALogP
4
HBA
2
HBD
48.4
PSA (Ų)
0.73
QED
0
Ro5 Violations
9
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1955 |
| Availability | Prescription |
| Chirality | Racemic |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Ferriprotoporphyrin IX inhibitor | INHIBITOR | Ferriprotoporphyrin IX | ✓ | ✓ |
| Toll-like receptor 7 antagonist | ANTAGONIST | Toll-like receptor 7 | ✓ | ✓ |
| Toll-like receptor 9 antagonist | ANTAGONIST | Toll-like receptor 9 | ✓ | ✓ |
Indications
Arthritis, Rheumatoid Malaria Coronavirus Infections Lung Diseases Lupus Erythematosus, Cutaneous Lupus Erythematosus, Systemic Severe Acute Respiratory Syndrome Antiphospholipid Syndrome Cholangiocarcinoma Lung Diseases, Interstitial Melanoma Melanoma Nephritis, Hereditary Pancreatic Neoplasms Rheumatic Diseases
Activity Summary
EC50 2 meas. best 5.38
IC50 2 meas. best 5.04
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| SARS-CoV-2 CHEMBL4303835 | EC50 | 5.38 | 5.335 | 4170.0 | 2 |
| SARS-CoV-2 CHEMBL4303835 | IC50 | 5.04 | 4.995 | 9210.0 | 2 |
Activity Data Samples
Top measurements by pChEMBL value
| Target | Type | Rel. | Value | Units | pChEMBL | Assay | PubMed |
|---|---|---|---|---|---|---|---|
| SARS-CoV-2 | EC50 | = | 4170.0 | nM | 5.38 | Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed... | - |
| SARS-CoV-2 | EC50 | = | 5090.0 | nM | 5.29 | Antiviral activity against SARS-CoV-2 infected in Vero E6 cells assessed as vira... | 34875467 |
| SARS-CoV-2 | IC50 | = | 9210.0 | nM | 5.04 | IC50 determination at MOI 0.004 using CellTiter- Glo (CTG) assay, performed 3 da... | - |
| SARS-CoV-2 | IC50 | = | 11170.0 | nM | 4.95 | IC50 determination at MOI 0.01 using CellTiter- Glo (CTG) assay, performed 3 day... | - |
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| - | 10.1101/2020.03.25.008482 | SARS-CoV-2 | 7 |
| 20485427 | 10.1038/nature09107 | Plasmodium falciparum | 4 |
| - | 10.1101/2020.04.03.023846 | SARS-CoV-2 | 3 |
| - | 10.6019/CHEMBL4495565 | SARS-CoV-2 | 2 |
| - | 10.1101/2020.04.21.054387 | SARS-CoV-2 | 2 |
| 34875467 | 10.1016/j.bmc.2021.116523 | SARS-CoV-2 | 2 |
| - | 10.1101/2020.03.25.008482 | ADMET | 2 |
| - | 10.1101/2020.03.25.008482 | Vero C1008 | 2 |
| 23956101 | 10.1093/toxsci/kft176 | Bile salt export pump | 1 |
| 23956101 | 10.1093/toxsci/kft176 | ATP-binding cassette sub-family C member 2 | 1 |
| 23956101 | 10.1093/toxsci/kft176 | ATP-binding cassette sub-family C member 3 | 1 |
| 23956101 | 10.1093/toxsci/kft176 | ATP-binding cassette sub-family C member 4 | 1 |
| - | 10.6019/CHEMBL3433997 | Glucose transporter | 1 |
| - | 10.6019/CHEMBL3433997 | Hexose transporter 1 | 1 |
| - | 10.6019/CHEMBL3433997 | Solute carrier family 2, facilitated glucose transporter member 1 | 1 |
| 23571415 | 10.1124/mol.112.084152 | Solute carrier organic anion transporter family member 1B1 | 1 |
| 34875467 | 10.1016/j.bmc.2021.116523 | ADMET | 1 |
| - | 10.1101/2020.04.03.023846 | ADMET | 1 |
| 23571415 | 10.1124/mol.112.084152 | Solute carrier organic anion transporter family member 1B3 | 1 |
| 20485427 | 10.1038/nature09107 | HepG2 | 1 |
Data from ChEMBL 36 via Core Engine